{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:55:05Z","timestamp":1771854905031,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s11096-020-01032-1","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T09:27:47Z","timestamp":1587634067000},"page":"853-860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Aspirin compared to enoxaparin or rivaroxaban for thromboprophylaxis following hip and knee replacement"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6174-0019","authenticated-orcid":false,"given":"Sadhbh","family":"N\u00ed Cheallaigh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5330-951X","authenticated-orcid":false,"given":"Aoife","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0110-324X","authenticated-orcid":false,"given":"Darren","family":"Dahly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eimear","family":"Kehoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brid","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7496-9477","authenticated-orcid":false,"given":"Laura J.","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"issue":"2_suppl","key":"1032_CR1","doi-asserted-by":"publisher","first-page":"e278S","DOI":"10.1378\/chest.11-2404","volume":"141","author":"Y Falck-Ytter","year":"2012","unstructured":"Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2_suppl):e278S\u2013325S. https:\/\/doi.org\/10.1378\/chest.11-2404.","journal-title":"Chest"},{"issue":"11","key":"1032_CR2","doi-asserted-by":"publisher","first-page":"800","DOI":"10.7326\/0003-4819-158-11-201306040-00004","volume":"158","author":"DR Anderson","year":"2013","unstructured":"Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013;158(11):800\u20136. https:\/\/doi.org\/10.7326\/0003-4819-158-11-201306040-00004.","journal-title":"Ann Intern Med"},{"issue":"7","key":"1032_CR3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.arth.2009.06.021","volume":"25","author":"KJ Bozic","year":"2010","unstructured":"Bozic KJ, Vail TP, Pekow PS, Maselli JH, Lindenauer PK, Auerbach AD, et al. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplast. 2010;25(7):1053\u201360. https:\/\/doi.org\/10.1016\/j.arth.2009.06.021.","journal-title":"J Arthroplast"},{"issue":"9","key":"1032_CR4","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.arth.2012.02.006","volume":"27","author":"SC Hamilton","year":"2012","unstructured":"Hamilton SC, Whang WW, Anderson BJ, Bradbury TL, Erens GA, Roberson JR. Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study. J Arthroplast. 2012;27(9):1594\u20138. https:\/\/doi.org\/10.1016\/j.arth.2012.02.006.","journal-title":"J Arthroplast"},{"issue":"3","key":"1032_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/BCO.0000000000000222","volume":"26","author":"DN Holden","year":"2015","unstructured":"Holden DN, Maceira E. Thromboembolism prophylaxis failure rates after hip and knee arthroplasty: comparison of aspirin and anticoagulants. Curr Orthop Pract. 2015;26(3):277\u201380. https:\/\/doi.org\/10.1097\/BCO.0000000000000222.","journal-title":"Curr Orthop Pract"},{"issue":"7","key":"1032_CR6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1302\/0301-620X.94B7.29129","volume":"94","author":"SS Jameson","year":"2012","unstructured":"Jameson SS, Baker PN, Charman SC, Deehan DJ, Reed MR, Gregg PJ, et al. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomised comparison using National Joint Registry Data. J Bone Jt Surg Br. 2012;94(7):914\u20138.","journal-title":"J Bone Jt Surg Br"},{"issue":"11","key":"1032_CR7","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1302\/0301-620x.93b11.27622","volume":"93 B","author":"SS Jameson","year":"2011","unstructured":"Jameson SS, Charman SC, Gregg PJ, Reed MR, Van Der Meulen JH. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry. J Bone Jt Surg Ser B. 2011;93 B(11):1465\u201370. https:\/\/doi.org\/10.1302\/0301-620x.93b11.27622.","journal-title":"J Bone Jt Surg Ser B"},{"issue":"2","key":"1032_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2106\/JBJS.16.00147","volume":"99","author":"J Parvizi","year":"2017","unstructured":"Parvizi J, Huang R, Restrepo C, Chen AF, Austin MS, Hozack WJ, et al. Low-dose aspirin is effective chemoprophylaxis against clinically important venous thromboembolism following total joint arthroplasty: a preliminary analysis. J Bone Jt Surg Am. 2017;99(2):91\u20138. https:\/\/doi.org\/10.2106\/JBJS.16.00147.","journal-title":"J Bone Jt Surg Am"},{"issue":"9212","key":"1032_CR9","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(00)02110-3","volume":"355","author":"Pulmonary Embolism Prevention trial Collaborative Group","year":"2000","unstructured":"Pulmonary Embolism Prevention trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial. Lancet. 2000;355(9212):1295\u2013302.","journal-title":"Lancet"},{"issue":"6","key":"1032_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.knee.2013.01.006","volume":"20","author":"NK Rath","year":"2013","unstructured":"Rath NK, Goodson MW, White SP, Forster MC. The use of rivaroxaban for chemical thromboprophylaxis following total knee replacement. Knee. 2013;20(6):397\u2013400. https:\/\/doi.org\/10.1016\/j.knee.2013.01.006.","journal-title":"Knee"},{"issue":"8","key":"1032_CR11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1712746","volume":"378","author":"DR Anderson","year":"2018","unstructured":"Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018;378(8):699\u2013707. https:\/\/doi.org\/10.1056\/NEJMoa1712746.","journal-title":"N Engl J Med"},{"issue":"7","key":"1032_CR12","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/j.arth.2018.03.001","volume":"33","author":"M Faour","year":"2018","unstructured":"Faour M, Piuzzi NS, Brigati DP, Klika AK, Mont MA, Barsoum WK, et al. Low-dose aspirin is safe and effective for venous thromboembolism prophylaxis following total knee arthroplasty. J Arthroplast. 2018;33(7):S131\u20135. https:\/\/doi.org\/10.1016\/j.arth.2018.03.001.","journal-title":"J Arthroplast"},{"issue":"7","key":"1032_CR13","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.arth.2015.02.009","volume":"30","author":"MA Charters","year":"2015","unstructured":"Charters MA, Frisch NB, Wessell NM, Dobson C, Les CM, Silverton CD. Rivaroxaban versus enoxaparin for venous thromboembolism prophylaxis after hip and knee arthroplasty. J Arthroplast. 2015;30(7):1277\u201380. https:\/\/doi.org\/10.1016\/j.arth.2015.02.009.","journal-title":"J Arthroplast"},{"issue":"10","key":"1032_CR14","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1111\/jth.12675","volume":"12","author":"A Lazo-Langner","year":"2014","unstructured":"Lazo-Langner A, Fleet JL, McArthur E, Garg AX. Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study. J Thromb Haemost. 2014;12(10):1626\u201335. https:\/\/doi.org\/10.1111\/jth.12675.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"1032_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00590-012-0987-y","volume":"23","author":"K Sindali","year":"2013","unstructured":"Sindali K, Rose B, Soueid H, Jeer P, Saran D, Shrivastava R. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. Eur J Orthop Surg Traumatol. 2013;23(4):481\u20136. https:\/\/doi.org\/10.1007\/s00590-012-0987-y.","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"1032_CR16","unstructured":"NICE. Venous thromboembolism in over 16\u00a0s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism [NG89]. 2018. https:\/\/www.nice.org.uk\/guidance\/ng89\/chapter\/Recommendations#interventions-for-people-having-orthopaedic-surgery. Accessed 21 Apr 2018."},{"key":"1032_CR17","unstructured":"Australian Commission on Safety and Quality in Health Care. Venous thromboembolism prevention clinical care standard. 2020. https:\/\/www.safetyandquality.gov.au\/sites\/default\/files\/2020-01\/venous_thromboembolism_prevention_clinical_care_standard_-_jan_2020_2.pdf. Accessed 18 Feb 2020."},{"key":"1032_CR18","unstructured":"Cappagh National Orthopaedic Hospital. Annual Report 2016. Ireland East Hospital Group. 2016. http:\/\/www.cappagh.ie\/sites\/default\/files\/pdf\/Annual%20Report%202016.pdf. Accessed 29 July 2017."},{"issue":"8","key":"1032_CR19","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1302\/0301-620x.98b8.36957","volume":"98-B","author":"DG Wilson","year":"2016","unstructured":"Wilson DG, Poole WE, Chauhan SK, Rogers BA. Systematic review of aspirin for thromboprophylaxis in modern elective total hip and knee arthroplasty. Bone Jt J. 2016;98-B(8):1056\u201361. https:\/\/doi.org\/10.1302\/0301-620x.98b8.36957.","journal-title":"Bone Jt J"},{"issue":"2","key":"1032_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/2515245918770963","volume":"1","author":"D Lakens","year":"2018","unstructured":"Lakens D, Scheel AM, Isager PM. Equivalence testing for psychological research: a tutorial. Adv Methods Pract Psychol Sci. 2018;1(2):259\u201369. https:\/\/doi.org\/10.1177\/2515245918770963.","journal-title":"Adv Methods Pract Psychol Sci"},{"issue":"5","key":"1032_CR21","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1093\/ije\/dyv137","volume":"44","author":"DB Richardson","year":"2015","unstructured":"Richardson DB, Kinlaw AC, MacLehose RF, Cole SR. Standardized binomial models for risk or prevalence ratios and differences. Int J Epidemiol. 2015;44(5):1660\u201372. https:\/\/doi.org\/10.1093\/ije\/dyv137.","journal-title":"Int J Epidemiol"},{"key":"1032_CR22","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2017. https:\/\/www.R-project.org\/. Accessed 10 July 2018."},{"issue":"2","key":"1032_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.arth.2011.04.006","volume":"27","author":"M Khatod","year":"2012","unstructured":"Khatod M, Inacio MC, Bini SA, Paxton EW. Pulmonary embolism prophylaxis in more than 30,000 total knee arthroplasty patients: Is there a best choice? J Arthroplast. 2012;27(2):167\u201372. https:\/\/doi.org\/10.1016\/j.arth.2011.04.006.","journal-title":"J Arthroplast"},{"issue":"6 SUPPL.","key":"1032_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.arth.2006.05.017","volume":"21","author":"GH Westrich","year":"2006","unstructured":"Westrich GH, Bottner F, Windsor RE, Laskin RS, Haas SB, Sculco TP. VenaFlow plus lovenox vs venaflow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. J Arthroplast. 2006;21(6 SUPPL.):139\u201343. https:\/\/doi.org\/10.1016\/j.arth.2006.05.017.","journal-title":"J Arthroplast"},{"issue":"7","key":"1032_CR25","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/MBC.0000000000000121","volume":"25","author":"Y Zou","year":"2014","unstructured":"Zou Y, Tian S, Wang Y, Sun K. Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. Blood Coag Fibrinol. 2014;25(7):660\u20134. https:\/\/doi.org\/10.1097\/MBC.0000000000000121.","journal-title":"Blood Coag Fibrinol"},{"issue":"6","key":"1032_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.arth.2009.06.002","volume":"24","author":"GA Brown","year":"2009","unstructured":"Brown GA. Venous thromboembolism prophylaxis after major orthopaedic surgery: a pooled analysis of randomized controlled trials. J Arthroplast. 2009;24(6):77\u201383.","journal-title":"J Arthroplast"},{"issue":"11","key":"1032_CR27","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.arth.2016.04.004","volume":"31","author":"VVG An","year":"2016","unstructured":"An VVG, Phan K, Levy YD, Bruce WJM. Aspirin as thromboprophylaxis in hip and knee arthroplasty: a\u00a0systematic review and meta-analysis. J Arthroplast. 2016;31(11):2608\u201316. https:\/\/doi.org\/10.1016\/j.arth.2016.04.004.","journal-title":"J Arthroplast"},{"key":"1032_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3675","author":"A G\u00f3mez-Outes","year":"2012","unstructured":"G\u00f3mez-Outes A, Terleira-Fern\u00e1ndez AI, Su\u00e1rez-Gea ML, Vargas-Castrill\u00f3n E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012. https:\/\/doi.org\/10.1136\/bmj.e3675.","journal-title":"BMJ"},{"issue":"2","key":"1032_CR29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/SLA.0b013e3181b7fca6","volume":"251","author":"V Bahl","year":"2010","unstructured":"Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg. 2010;251(2):344\u201350.","journal-title":"Ann Surg"},{"key":"1032_CR30","unstructured":"NICE. Venous thromboembolism: reducing the risk for patients in hospital CG92. 2010 (Updated 2015). https:\/\/www.nice.org.uk\/guidance\/cg92\/evidence\/full-guideline-pdf-243920125. Accessed May 2017."},{"issue":"23 Suppl 1","key":"1032_CR31","first-page":"9","volume":"107","author":"FA Anderson","year":"2003","unstructured":"Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):9\u201316.","journal-title":"Circulation"},{"issue":"8","key":"1032_CR32","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","volume":"12","author":"JA Heit","year":"2015","unstructured":"Heit JA. Epidemiology of venous thromboembolism. Nat Revi Cardiol. 2015;12(8):464\u201374. https:\/\/doi.org\/10.1038\/nrcardio.2015.83.","journal-title":"Nat Revi Cardiol"},{"issue":"3","key":"1032_CR33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11739-011-0567-x","volume":"7","author":"D Imberti","year":"2012","unstructured":"Imberti D, Bianchi C, Zambon A, Parodi A, Merlino L, Gallerani M, et al. Venous thromboembolism after major orthopaedic surgery: a population-based cohort study. Intern Emerg Med. 2012;7(3):243\u20139. https:\/\/doi.org\/10.1007\/s11739-011-0567-x.","journal-title":"Intern Emerg Med"},{"issue":"26","key":"1032_CR34","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"BI Eriksson","year":"2008","unstructured":"Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765\u201375. https:\/\/doi.org\/10.1056\/NEJMoa0800374.","journal-title":"N Engl J Med"},{"issue":"4","key":"1032_CR35","doi-asserted-by":"publisher","first-page":"358","DOI":"10.5482\/HAMO-14-12-0078","volume":"35","author":"M Heckmann","year":"2015","unstructured":"Heckmann M, Thermann H, Heckmann F. Rivaroxaban versus high dose nadroparin for thromboprophylaxis after hip or knee arthroplasty. H\u00e4mostaseologie. 2015;35(4):358\u201363. https:\/\/doi.org\/10.5482\/HAMO-14-12-0078.","journal-title":"H\u00e4mostaseologie"},{"issue":"9632","key":"1032_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0140-6736(08)60880-6","volume":"372","author":"AK Kakkar","year":"2008","unstructured":"Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(08)60880-6.","journal-title":"Lancet"},{"issue":"26","key":"1032_CR37","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"MR Lassen","year":"2008","unstructured":"Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776\u201386. https:\/\/doi.org\/10.1056\/NEJMoa076016.","journal-title":"N Engl J Med"},{"issue":"9676","key":"1032_CR38","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/s0140-6736(09)60734-0","volume":"373","author":"AG Turpie","year":"2009","unstructured":"Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673\u201380. https:\/\/doi.org\/10.1016\/s0140-6736(09)60734-0.","journal-title":"Lancet"},{"issue":"6","key":"1032_CR39","doi-asserted-by":"publisher","first-page":"381S","DOI":"10.1378\/chest.08-0656","volume":"133","author":"WH Geerts","year":"2008","unstructured":"Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2008;133(6):381S\u2013453S.","journal-title":"Chest"},{"issue":"17","key":"1032_CR40","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.2106\/JBJS.K.00521","volume":"94","author":"SS Jameson","year":"2012","unstructured":"Jameson SS, Rymaszewska M, James P, Serrano-Pedraza I, Muller SD, Hui AC, et al. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty. J Bone Jt Surg. 2012;94(17):1554\u20138.","journal-title":"J Bone Jt Surg"},{"issue":"1","key":"1032_CR41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1302\/0301-620X.93B1.24987","volume":"93","author":"C Jensen","year":"2011","unstructured":"Jensen C, Steval A, Partington P, Reed M, Muller S. Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban. Bone Jt J. 2011;93(1):91\u20135.","journal-title":"Bone Jt J"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01032-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-020-01032-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01032-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:26:17Z","timestamp":1619137577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-020-01032-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1032"],"URL":"https:\/\/doi.org\/10.1007\/s11096-020-01032-1","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"5 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}